Barclays raised the firm’s price target on Alignment Healthcare (ALHC) to $9 from $8 and keeps an Underweight rating on the shares following the Q4 EBITDA beat.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALHC:
- Alignment Healthcare: Strong Financial Performance and Promising Outlook Justify Buy Rating
- Alignment Healthcare Reports Strong Growth and Positive Outlook
- Alignment Healthcare reports Q4 EPS (16c), consensus (8c)
- Alignment Healthcare sees Q1 adjusted EBITDA $2M-$10M
- Alignment Healthcare sees FY25 adjusted EBITDA $35M-$60M